Mark Gotfried
Pulmonary Disease · Phoenix, AZNPI 1952353658
Payments from drug & device makers
Across 420 payments — averaging $2566.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$245K
- Takeda Pharmaceuticals U.S.A., Inc.$219K
- Eisai Inc.$196K
- GSK$147K
- Melinta Therapeutics, LLC$71K
- CSL Behring$70K
- plus $131K from 12 others
Across 17 payments — averaging $167.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$3K
What the payments were for
- Consulting fees$4500%
- Speaking & faculty fees$182,44893%
- Travel & lodging$11,2096%
- Food & beverage$2,1491%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 68 | $245,100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 65 | $218,522 |
| Eisai Inc. | 20 | $195,501 |
| GSK | 126 | $147,018 |
| Melinta Therapeutics, LLC | 1 | $70,523 |
| CSL Behring | 25 | $70,394 |
| AstraZeneca | 6 | $65,692 |
| Idorsia Pharmaceuticals US Inc | 79 | $45,872 |
| Shionogi Inc | 4 | $10,000 |
| Novartis | 1 | $6,029 |
| Mylan Specialty L.p. | 1 | $1,800 |
| Insmed, Inc. | 3 | $1,224 |
| Sunovion Pharmaceuticals Inc. | 6 | $133 |
| ZOLL Respicardia, Inc. | 6 | $124 |
| Gilead | 4 | $53 |
| Genentech USA, Inc. | 2 | $43 |
| Bayer | 2 | $38 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$84,064
- QUVIVIQ$44,092
- NUCALA$23,656
- ANORO ELLIPTA$18,000
- ANORO$11,354
- Yupelri$1,800
- Arikayce$1,125
How this compares
$1,078,079 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Abid KhokarPhoenix$321K
- Brian PorvinPhoenix$276K
- Tony HodgesPhoenix$262K
- Rajeev SaggarPhoenix$219K
- Ali SaeedPhoenix$213K
- Bhuvin BuddhdevPhoenix$202K
- Gregory AhearnPhoenix$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.